Bronchiectasis AdultNCT06906354
Airway Clearance by Fiberoptic Bronchoscopy in Bronchiectasis Followed by Gentamicin and Dexamethason Injection
A study testing Airway Clearance by Fiberoptic Bronchoscopy in Bronchiectasis Followed by Gentamicin and Dexamethason Injection in people with Bronchiectasis Adult and Bronchiectasis With Acute Exacerbation, run by Alexandria University at 1 site in Egypt.
Trial summary
Fiberoptic Bronchoscopic Removal of Secretions and Antibiotic Injection Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Bronchiectasis Adult, Bronchiectasis With Acute Exacerbation
- What is being tested?
- Airway Clearance by Fiberoptic Bronchoscopy in Bronchiectasis Followed by Gentamicin and Dexamethason Injection
- Type of treatment
- Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 siteEgypt
- Study dates
- 11 Nov 2024to 20 Jan 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- 1- Adult subjects. 2- Male and female subjects are enrolled. 3- patients with NCFB confirmed by chest high-resolution computed tomography (HRCT) 4- patients needing antibiotic treatment at the hospital due to exacerbation 5- Patients who underwent AC by bronchoscopy at the hospital.
- -
Who cannot join
- 1- Uncooperative subjects. 2- Unwilling to participate. 3- Inability to lie on the back with raised arms over the head for HRCT. 4- Presence of cystic pulmonary fibrosis; 5- Patients with active pulmonary tuberculosis; 6- Those awaiting surgery; 7- Patients who underwent interventional therapy for hemoptysis; those with allergic bronchopulmonary aspergillosis (ABPA); 8- Patients who did not undergo bronchoscopy for different reasons or combined with lung cancer.
- -
Trial locations and contacts
1 site in 1 country.
About this study
Official title: The Effect of Intrabronchial Therapy With Gentamycin and Dexamethason After Bronchoscopic Airway Clearance in Exacerbation of Bronchiectasis
Fiberoptic Bronchoscopic Removal of Secretions and Antibiotic Injection
Read the detailed description
fiberoptic bronchoscopic injection of dexamethason and gentamicin after airway clearance
- Being tested
- Airway Clearance by Fiberoptic Bronchoscopy in Bronchiectasis Followed by Gentamicin and Dexamethason Injection
- Keywords
- bronchoscopy, bronchiectasis
- Medical subject headings
- Bronchiectasis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Airway Clearance by Fiberoptic Bronchoscopy in Bronchiectasis Followed by Gentamicin and Dexamethason InjectionProcedure or surgery
Airway Clearance by Fiberoptic Bronchoscopy in Bronchiectasis Followed by Gentamicin and Dexamethason Injection
| Study group | Role | What they receive |
|---|---|---|
| fiberoptic bronchoscopy in one group | Active comparator | Airway Clearance by Fiberoptic Bronchoscopy in Bronchiectasis Followed by Gentamicin and Dexamethason Injection Receives: Procedure: Airway Clearance by Fiberoptic Bronchoscopy in Bronchiectasis Followed by Gentamicin and Dexamethason Injection |
What is being measured
The primary outcome is the main question the study is designed to answer.
Dyspnea Borg Scale
improvement in the scale of dyspnea before and after the procedure
Measured: one month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Apr 2025
- Study start11 Nov 2024
- Primary completion15 Jan 2025
- Study completion20 Jan 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Bronchiectasis AdultStudies of the same condition, open and under way.
- More trials run by Alexandria UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Fiberoptic Airway Clearance in Bronchiectasis Exacerbation and Gentamicin-Dexamethason Injection
- Masking
- None (open label)
- Enrolment
- 60 participants (actual)
Sponsor and investigators
- Lead sponsor
- Alexandria University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- mohamed sabry Eltarhony, lecturer, Principal investigator, Alexandria University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06906354
- Sponsor's protocol ID
- bronchiectasis FOB
- Status last verified
- Jan 2025
- First submitted
- 26 Mar 2025
- Last updated
- 2 Apr 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: i will do it after being accepted from the ethics committee
Study at a glance
From the registry record, last updated by the sponsor on 2 Apr 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of Intrabronchial Therapy With Gentamycin and Dexamethason After Bronchoscopic Airway Clearance in Exacerbation of Bronchiectasis
- ClinicalTrials.gov ID
- NCT06906354
- Acronym / sponsor ID
- bronchiectasis FOB
- Keywords
- bronchoscopy, bronchiectasis
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 60 participants (actual)
- Lead sponsor
- Alexandria UniversityUniversity, hospital or other
- Study start
- 11 Nov 2024 (actual)
- Primary completion
- 15 Jan 2025 (actual)
- Study completion
- 20 Jan 2025 (actual)
- First posted
- 2 Apr 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Fiberoptic Bronchoscopic Removal of Secretions and Antibiotic Injection
Detailed description
fiberoptic bronchoscopic injection of dexamethason and gentamicin after airway clearance
Study design
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Fiberoptic Airway Clearance in Bronchiectasis Exacerbation and Gentamicin-Dexamethason Injection
| Arm | Type | Receives |
|---|---|---|
| fiberoptic bronchoscopy in one group | Active comparator | Procedure: Airway Clearance by Fiberoptic Bronchoscopy in Bronchiectasis Followed by Gentamicin and Dexamethason InjectionAirway Clearance by Fiberoptic Bronchoscopy in Bronchiectasis Followed by Gentamicin and Dexamethason Injection |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (2 listed)
- 1- Adult subjects. 2- Male and female subjects are enrolled. 3- patients with NCFB confirmed by chest high-resolution computed tomography (HRCT) 4- patients needing antibiotic treatment at the hospital due to exacerbation 5- Patients who underwent AC by bronchoscopy at the hospital.
- -
Key exclusion criteria (2 listed)
- 1- Uncooperative subjects. 2- Unwilling to participate. 3- Inability to lie on the back with raised arms over the head for HRCT. 4- Presence of cystic pulmonary fibrosis; 5- Patients with active pulmonary tuberculosis; 6- Those awaiting surgery; 7- Patients who underwent interventional therapy for hemoptysis; those with allergic bronchopulmonary aspergillosis (ABPA); 8- Patients who did not undergo bronchoscopy for different reasons or combined with lung cancer.
- -
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Airway Clearance by Fiberoptic Bronchoscopy in Bronchiectasis Followed by Gentamicin and Dexamethason InjectionAirway Clearance by Fiberoptic Bronchoscopy in Bronchiectasis Followed by Gentamicin and Dexamethason Injection | Procedure or surgery | fiberoptic bronchoscopy in one group |
Primary outcome
Dyspnea Borg Scale
Time frame: one month
improvement in the scale of dyspnea before and after the procedure
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Apr 2025.
- bronchoscopy in bronchiectasisLink provided by the sponsor.
- fiberoptic bronchoscopy in bronchiectasisLink provided by the sponsor.
- Individual participant dataSharing planned: Undecided. i will do it after being accepted from the ethics committee
Related trials for Bronchiectasis Adult
RecruitingPhase 2
A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Adult Study Participants With Non-Cystic Fibrosis Bronchiectasis
Non-cystic Fibrosis Bronchiectasis
RecruitingPhase 3
Compare Oral Itraconazole and Standard Care Versus Standard Care Alone in Patients With Non-cystic Fibrosis Related Bronchiectasis With Chronic Aspergillus Infection in Reducing Bronchiectasis Exacerbations
Bronchiectasis, Bronchiectasis Adult
RecruitingPhase 2
Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fibrosis Bronchiectasis (NCFB)
Non-cystic Fibrosis Bronchiectasis
Active, not recruitingPhase 1
A Phase 1a/1b Study to Investigate the Safety, Tolerability, Microbiological Response, and Pharmacokinetics of Inhaled Rev-56 in Adult Healthy Volunteers and Adult Non-cystic Fibrosis Bronchiectasis (NCFB) Patients With Chronic P. Aeruginosa
Healthy Participants, Non-cystic Fibrosis Bronchiectasis
RecruitingPhase 4
Azithromycin to Modify Bronchiectasis Exacerbation Risk
Non-cystic Fibrosis Bronchiectasis, Bronchiectasis Adult
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
mohamed sabry Eltarhony, lecturer principal investigator
Alexandria University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Airway Clearance by Fiberoptic Bronchoscopy in Bronchiectasis Followed by Gentamicin and Dexamethason Injection in people with Bronchiectasis Adult and Bronchiectasis With Acute Exacerbation, run by Alexandria University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Dyspnea Borg Scale (time frame: one month). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Apr 2025.